Fortrea Holdings Reports 3.9% Revenue Growth in Q3 2025, Operating Loss Improves

Fortrea Holdings Inc. reported its financial results for the third quarter of 2025, revealing a revenue increase of 3.9% to $701.3 million compared to $674.9 million in the same period of 2024. For the nine months ending September 30, 2025, revenues reached $2.06 billion, a 3.2% rise from $1.999 billion in the prior year. The growth was attributed to a 3.5% increase in organic revenues, driven by higher demand in clinical pharmacology and clinical development services, alongside favorable foreign currency translation effects.

The company's operating loss for the third quarter was $8.6 million, an improvement from a loss of $18.0 million in the same quarter of 2024. However, for the nine-month period, the operating loss significantly widened to $859 million, primarily due to a goodwill impairment charge of $797.9 million recorded in the second quarter. This impairment was linked to the Clinical Development reporting unit, reflecting a decline in the unit's fair value amid challenging market conditions. The net loss for the third quarter was $15.9 million, compared to a loss of $27.9 million in the prior year, while the nine-month net loss escalated to $953.7 million from $267.3 million.

In terms of operational metrics, Fortrea's total assets decreased to $2.74 billion as of September 30, 2025, down from $3.58 billion at the end of 2024. The company’s cash and cash equivalents increased to $131.3 million, up from $118.5 million at the end of 2024. The total equity also saw a significant decline, dropping to $580.8 million from $1.36 billion, largely due to the accumulated deficit which increased to $1.35 billion. The company’s employee headcount remained stable at over 14,500, supporting its operations across approximately 100 countries.

Strategically, Fortrea has focused on streamlining its operations following the sale of its Enabling Services Segment in March 2024, which was a significant shift in its business model. The company received milestone payments totaling $45 million related to this sale, with $25 million received in the third quarter of 2025. Fortrea continues to leverage its global scale and expertise in clinical development to meet the growing demand for biopharmaceutical services. Looking ahead, the company anticipates that its existing cash and cash flows will be sufficient to support operations for at least the next 12 months, while also exploring potential acquisitions and investments to drive growth.